MedPage Today Well, I wonder if we can shift our focus a little bit now as we have this discussion here at ASCO about abstracts to an area that is clearly a hot topic. I mean, if there were three letters that are included in every single myeloma meeting in the year 2024, and I'm going to suggest 2025, it's the letters MRD, right? Minimal residual disease, or some who like to have now adjusted to be measurable residual disease. So whether you're a minimal or a measurable, whatever, two parties you're part of, let's come together and have this discussion.

And I say it a little bit tongue in cheek, but it really is remarkable. We've had a recent ODAC [Oncologic Drugs Advisory Committee] review of whether or not MRD can be used as a clinical trial endpoint that we hope will facilitate and clearly speed up drug development. And the ODAC voted 12-0 in favor of this concept.

Obviously, that's a recommendation to the FDA. The FDA is not bound by that. I don't necessarily want to focus as much about the clinical trial endpoint, but really about the value of MRD.

And we have a really important abstract here at ASCO, which is building on the history of the trial. The MASTER trial was giving D-KRd [daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone] to patients in an ongoing fashion, incorporating a transplant, but trying to deescalate patients based on their MRD or what they call the MRD-SURE status, that you become MRD twice, MRD negative on at l.